Cohance Lifesciences Ltd files SEBI disclosure of share acquisition by CSC Global Capital Markets (Singapore)

What Cohance Lifesciences announced

Cohance Lifesciences Ltd (BSE: 543064) filed a disclosure on 19 June 2026 with the Bombay Stock Exchange, indicating that CSC Global Capital Markets (Singapore) Pte Ltd has undertaken a substantial acquisition of its shares. The filing is made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, which requires companies to inform the market when a party acquires a shareholding that meets the statutory threshold for a ‘substantial acquisition.’

"The Exchange has received the disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for CSC Global Capital Markets (Singapore) Pte Ltd."

The announcement does not disclose the exact number of shares, the percentage of the total equity acquired, nor the consideration paid.

Disclosure under SEBI Regulation 29(2)

Regulation 29(2) mandates that any person acquiring shares which, when aggregated with any existing holdings, crosses the 5 % threshold of a listed company's paid‑up capital must file a disclosure with the stock exchange. The filing must be made within two trading days of the acquisition. The purpose is to ensure transparency for investors and to trigger any mandatory takeover obligations under the SAST framework.

In this case, the filing confirms that CSC Global Capital Markets (Singapore) Pte Ltd has crossed the applicable threshold, prompting the required disclosure. No further details—such as the exact shareholding percentage, the price paid, or the strategic rationale—are provided in the document.

Key facts at a glance

Why this matters for investors

The filing signals that a foreign investor has taken a material stake in Cohance Lifesciences Ltd, which could affect the company’s shareholding pattern and potentially trigger additional regulatory requirements, such as a mandatory open offer if the acquirer’s holding exceeds 25 % of the equity. However, because the exact percentage and price are not disclosed, investors cannot assess the immediate financial impact or the strategic intent behind the acquisition. The disclosure does, however, provide regulatory transparency and alerts shareholders to a change in the ownership structure.

Conclusion

Cohance Lifesciences Ltd has complied with SEBI’s disclosure requirements by reporting that CSC Global Capital Markets (Singapore) Pte Ltd has made a substantial share acquisition, as of 19 June 2026. While the filing confirms the occurrence of a material transaction, it does not reveal the size of the stake or the terms of the deal. Investors will need to await any subsequent filings or shareholder communications for a fuller picture of the transaction’s implications.